KYSE410
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The KYSE410 cell line was derived from a poorly differentiated invasive esophageal squamous cell carcinoma located in the cervical esophagus of a 51-year-old Japanese male prior to any treatment. These cells exhibit notable overexpression of heparin binding growth factor (hst-1) and cyclin D1. They display an epithelioid morphology, forming adherent monolayers in culture with a doubling time ranging from 32 to 45 hours. Subculturing is performed by splitting confluent cells at ratios of 1:4 to 1:6 approximately every 2 to 3 times per week.
Why choose KYSE410 from AcceGen?
KYSE410 from AcceGen offers high-quality and highly viable cells. They are maintained in a sterile environment with stringent daily monitoring for bacterial and fungal contamination. These cells are certified pathogen-free, being negative for EBV, HBV, HCV, HHV-8, HIV-1, HIV-2, HPV, HTLV-1/2, MLV, and SMRV via PCR analysis. Identity is confirmed through STR analysis.
| Product Code | KYSE 410; KYSE410; Kyse410; KYSE0410 |
| Species | Human |
| Cat.No | ABC-TC1333 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Esophageal Squamous Cell Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Human Esophageal Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The KYSE410 cell line serves as a valuable tool in the research of human esophageal carcinoma, specifically for investigating the intricate mechanisms underlying cell proliferation and invasion in esophageal squamous cell cancer. Additionally, it plays a crucial role in elucidating the key factors contributing to the radioresistance of esophageal cancer cells. These applications enable scientists to gain a deeper understanding of the disease and develop potential therapeutic strategies to combat esophageal cancer more effectively.
